Диссертация (1140309), страница 21
Текст из файла (страница 21)
— Р. 12-23.116. Sewak S., Kosmider S., Ganju V., Woollett A., Yeow E.G., Le B., HenryM., Debrincat M.A., Bell R. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) inhormone-refractory metastatic prostate cancer: double tubulin targeting // Intern Med J.2010. Т. 40. № 3. — Р. 201-8.117.
Shah R.B., Mehra R., Chinnaiyan A.M., Shen R., Ghosh D., Zhou M.,Macvicar G.R., Varambally S., Harwood J., Bismar T.A., Kim R., Rubin M.A., PientaK.J. Androgen-independent prostate cancer is a heterogeneous group of diseases:lessons from a rapid autopsy program // Cancer Res. 2004. Т. 64. № 24. — Р. 9209-16.119118. Shelley M., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D.Chemotherapy for hormone-refractory prostate cancer // Cochrane Database Syst Rev.2006. № 4.
— Р. CD005247.119. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015 // CA Cancer JClin. 2015. Т. 65. № 1. — Р. 5-29.120. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K.,Kelly W.K., Kattan M.W. Nomogram for overall survival of patients with progressivemetastatic prostate cancer after castration // J Clin Oncol. 2002. Т.
20. № 19. — Р.3972-82.121. Smith D.C., Dunn R.L., Strawderman M.S., Pienta K.J. Change in serumprostate-specific antigen as a marker of response to cytotoxic therapy for hormonerefractory prostate cancer // J Clin Oncol. 1998. Т. 16. № 5. — Р. 1835-43.122. Smith D.C., Jodrell D.I., Egorin M.J., Ambinder R.M., Zuhowski E.G.,Kreis W., Ellis P.G., Trump D.L. Phase II trial and pharmacokinetic assessment ofintravenous melphalan in patients with advanced prostate cancer // Cancer ChemotherPharmacol. 1993.
Т. 31. № 5. — Р. 363-8.123. Smith P.H., Bono A., Calais da Silva F., Debruyne F., Denis L., RobinsonP., Sylvester R., Armitage T.G. Some limitations of the radioisotope bone scan inpatients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. TheEORTC Urological Group // Cancer.
1990. Т. 66. № 5 Suppl. — Р. 1009-16.124. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of thePTEN tumour suppressor // Nat Rev Mol Cell Biol. 2012. Т. 13. № 5. — Р. 283-96.125. Sridhar S.S., Freedland S.J., Gleave M.E., Higano C., Mulders P., ParkerC., Sartor O., Saad F. Castration-resistant prostate cancer: from new pathophysiology tonew treatment // Eur Urol.
2014. Т. 65. № 2. — Р. 289-99.126. Stein C.A. Mechanisms of action of taxanes in prostate cancer // SeminOncol. 1999. Т. 26. № 5 Suppl 17. — Р. 3-7.127. Stein M.N., Goodin S., Dipaola R.S. Abiraterone in prostate cancer: a newangle to an old problem // Clin Cancer Res. 2012. Т.
18. № 7. — Р. 1848-54.120128. Stein M.N., Patel N., Bershadskiy A., Sokoloff A., Singer E.A. Androgensynthesis inhibitors in the treatment of castration-resistant prostate cancer // Asian JAndrol. 2014. Т. 16. № 3. — Р. 387-400.129. Steketee K., Timmerman L., Ziel-van der Made A.C., Doesburg P.,Brinkmann A.O., Trapman J. Broadened ligand responsiveness of androgen receptormutants obtained by random amino acid substitution of H874 and mutation hot spotT877 in prostate cancer // Int J Cancer.
2002. Т. 100. № 3. — Р. 309-17.130. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N.,Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A.,Investigators T.A.X. Docetaxel plus prednisone or mitoxantrone plus prednisone foradvanced prostate cancer // N Engl J Med.
2004. Т. 351. № 15. — Р. 1502-12.131. Tannock I.F., Fizazi K., Ivanov S., Karlsson C.T., Flechon A., SkonecznaI., Orlandi F., Gravis G., Matveev V., Bavbek S., Gil T., Viana L., Aren O., KaryakinO., Elliott T., Birtle A., Magherini E., Hatteville L., Petrylak D., Tombal B., RosenthalM., investigators V. Aflibercept versus placebo in combination with docetaxel andprednisone for treatment of men with metastatic castration-resistant prostate cancer(VENICE): a phase 3, double-blind randomised trial // Lancet Oncol.
2013. Т. 14. № 8.— Р. 760-8.132. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., MooreM.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M., Murphy K.C.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatichormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints // J Clin Oncol. 1996. Т. 14. № 6. — Р. 1756-64.133. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B.,Balk S.P. Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist // Cancer Res.
1999. Т. 59. № 11. — Р. 2511-5.134. Taylor C.D., Elson P., Trump D.L. Importance of continued testicularsuppression in hormone-refractory prostate cancer // J Clin Oncol. 1993. Т. 11. № 11.— Р. 2167-72.121135. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., SunX.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B.,Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETStranscription factor genes in prostate cancer // Science. 2005.
Т. 310. № 5748. — Р.644-8.136. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.Global cancer statistics, 2012 // CA Cancer J Clin. 2015. Т. 65. № 2. — Р. 87-108.137. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., WongvipatJ., Smith-Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D.,Higano C.S., Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L.
Developmentof a second-generation antiandrogen for treatment of advanced prostate cancer //Science. 2009. Т. 324. № 5928. — Р. 787-90.138. Ueda Y., Matsubara N., Tabata K.I., Satoh T., Kamiya N., Suzuki H.,Kawahara T., Uemura H. Prostate-Specific Antigen Flare Phenomenon Induced byAbiraterone Acetate in Chemotherapy-Naive Patients With Metastatic CastrationResistant Prostate Cancer // Clin Genitourin Cancer. 2017. Т. 15. № 2. — Р.
320-325.139. van Brussel J.P., Busstra M.B., Lang M.S., Catsburg T., Schroder F.H.,Mickisch G.H. A phase II study of temozolomide in hormone-refractory prostate cancer// Cancer Chemother Pharmacol. 2000. Т. 45. № 6. — Р. 509-12.140. Van Praet C., Rottey S., Van Hende F., Pelgrims G., Demey W., Van AelstF., Wynendaele W., Gil T., Schatteman P., Filleul B., Schallier D., Machiels J.P.,Schrijvers D., Everaert E., D'Hondt L., Werbrouck P., Vermeij J., Mebis J., Clausse M.,Rasschaert M., Van Erps J., Verheezen J., Van Haverbeke J., Goeminne J.C., Lumen N.Which Factors Predict Overall Survival in Patients With Metastatic Castration-ResistantProstate Cancer Treated With Abiraterone Acetate Post-Docetaxel? // Clin GenitourinCancer. 2017.141.
Wang S.I., Parsons R., Ittmann M. Homozygous deletion of the PTENtumor suppressor gene in a subset of prostate adenocarcinomas // Clin Cancer Res.1998. Т. 4. № 3. — Р. 811-5.122142. Williamson S.K., Wolf M.K., Eisenberger M.A., O'Rourke M.A., BrannonW., Crawford E.D. Phase II evaluation of ifosfamide/mesna in metastatic prostatecancer. A Southwest Oncology Group study // Am J Clin Oncol. 1996.
Т. 19. № 4. — Р.368-70.143. Witte R.S., Yeap B.Y., Trump D.L. Trimetrexate in advanced hormonerefractory prostate cancer. An ECOG phase II trial // Invest New Drugs. 1994. Т. 12. №3. — Р. 255-8.144. Xie W., Nakabayashi M., Regan M.M., Oh W.K. Higher prostate-specificantigen levels predict improved survival in patients with hormone-refractory prostatecancer who have skeletal metastases and normal serum alkaline phosphatase // Cancer.2007. Т. 110. № 12.
— Р. 2709-15.145. Yang K.W., Yu W., Song Y., Huang L.H., Han W.K., He Z.S., Jin J., ZhouL.Q. [Predictor analysis of PSA response of docetaxel combined with prednisone in thetreatment of metastatic castration resistant prostate cancer] // Beijing Da Xue Xue Bao.2015. Т. 47. № 4. — Р. 592-6.146. Yap T.A., Pezaro C.J., de Bono J.S. Cabazitaxel in metastatic castrationresistant prostate cancer // Expert Rev Anticancer Ther.
2012. Т. 12. № 9. — Р. 1129-36.147. Z. Zafeiriou, R. Ferraldeschi, A.G. Omlin, C. Pezaro, D. Mukherji, D.Lorente, A. Altavilla, S. Sideris, P. Rescigno, J. Mateo, D. Bianchini, A. Smith, R. PerezLopez, N. Mehra, P. Ravi, E. Grist, N. Tunariu, G. Attard, Bono J.S.D. Sequencing ofdocetaxel (D) and abiraterone acetate (AA) for metastatic castration-resistant prostatecancer (mCRPC) // Annals of Oncology: Official Journal of the European Society forMedical Oncology. 2014. Т.
ESMO 2014: 25 (suppl 4 abstract 791P)..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
